Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified. In this retrospective multicentre observational study, based on a previous analysis that included 501 adult patients with severe AD (Eczema Area and Severity Index [EASI] ≥24 at baseline, contraindication, side-effects or failure in respect to cyclosporine according to the Italian Drug Agency [AIFA] recommendations) treated with dupilumab from ten Italian allergological/dermatological centres during September 2018-April 2020, we aimed at investigating patients’ baseline factors influencing treatment outcome and time to treatment response. No wash-out period was required. Any topical approved AD treatments were permitted as needed. Patients receiving systemic treatments during dupilumab therapy were excluded from the study.
Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response
Di Leo, E;Foti, C;Patruno, C;Macchia, L;Di Bona, D;
2021-01-01
Abstract
Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified. In this retrospective multicentre observational study, based on a previous analysis that included 501 adult patients with severe AD (Eczema Area and Severity Index [EASI] ≥24 at baseline, contraindication, side-effects or failure in respect to cyclosporine according to the Italian Drug Agency [AIFA] recommendations) treated with dupilumab from ten Italian allergological/dermatological centres during September 2018-April 2020, we aimed at investigating patients’ baseline factors influencing treatment outcome and time to treatment response. No wash-out period was required. Any topical approved AD treatments were permitted as needed. Patients receiving systemic treatments during dupilumab therapy were excluded from the study.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
